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(CFTR) belongs to the ATP-binding cassette superfamily and
mediates the transport of chloride and bicarbonate through
epithelial cell membranes. Mutations in the human CFTR gene
cause cystic fibrosis (CF) [1], and more than 90% of CF patients
are either homozygous or compound heterozygous for the 3-bp in-
frame deletion F508del [2]. F508del CFTR is the most common,
potentially fatal mutation in Caucasian populations. Although data
is conflicting to what extent F508del CFTR can be processed and
remains functional in CF patients’ epithelia, in vitro studies
consistently demonstrated that F508del CFTR is a temperature-
sensitive mutant, defective in protein maturation [3]. F508del
CFTR is unable to adopt a protease-resistant mature conformation
that enables exit from the endoplasmic reticulum (ER) and
processing in the Golgi compartment. The ER quality control [4]
leads to ER retention, retrotranslocation and ultimately to
cytoplasmic degradation of mutant CFTR by the ubiquitin-
proteasome pathway [5,6].Wild-type and F508del-CFTR undergo
ER-associated degradation (ERAD) from two distinct checkpoints,
the mutant being disposed of independently of N-glycosidic
residues and calnexin, probably by the Hsc70/Hsp70 machinery,
and wild type CFTR undergoing glycan-mediated ERAD [7]. If
F508del CFTR is processed at the permissive temperature and
delivered to the plasma membrane, the mutant exhibits reduced
channel open probability and sensitivity to stimulation with cAMP
agonists [8], and rapidly disappears from, and does not return to the
cell surface due to decreased conformational stability [9,10].
Mutant CFTR is the target for the treatment of the basic defect in
CF and researchers are currently screening for correctors of
defective F508del CFTR folding/cellular processing (“correctors”)
and channel gating (“potentiators”) [11].⁎ Tel.: +49 511 5322920; fax: +49 511 5326723.
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doi:10.1016/j.bbamem.2006.03.033John R. Riordan co-discovered the CFTR gene and its major
CF mutation in 1989 [12] and has published numerous seminal
papers on CFTR structure and biochemistry. His group has now
solved another mystery of CFTR that is relevant for any future
pharmacological therapy of CF. Based on a previous study [13],
Hegedus et al. report in this issue of the Journal that the
inactivation of two of the four arginine-framed tripeptide signals
in CFTR, R29-Q30-R31 at the N-terminus and R553-A554-
R555 in the cytosolic nucleotide-binding fold NBF1 is
necessary and sufficient to promote trafficking of F508del
CFTR towards the plasma membrane. The rescued mutant,
however, remains thermolabile indicating that the deletion of
F508 which is also located in NBF1 causes both a defect in
protein folding and stability at 37 °C.
Arginine-based ER-localization signals are sorting motifs that
are involved in the biosynthetic transport ofmultimericmembrane
proteins [14]. These motifs are located in the cytoplasmic regions
of polytopic membrane proteins that are subunits of membrane
protein complexes; the presence of the signal maintains
improperly assembled subunits in the ER until it is masked as a
result of heteromultimeric assembly [14]. CFTR is the first case
demonstrating that the Arg-based ER sorting motif couples the
control of folding with the forward transport of membrane
proteins. As long as the twoRXR signals in theN-terminal tail and
in the dodecapetide motif are exposed during folding, CFTR is
retained in the ER. Simultaneous substitution of one arginine by a
lysine in each of the two RXR tripeptides of F508del CFTR was
necessary and sufficient to escape the ER quality control and to
reach the plasma membrane. This finding is surprising in the light
of a recent report [15] that the diacidic D565-A566-D567 motif in
NBF1 is essential for the exit of CFTR from the ER. According to
the new data by Hegedus et al., the diacidic signal motif is less
relevant to the fate of F508del CFTR than the two RXR motifs in
the N-terminal tail and the dodecapeptide.
564 B. Tümmler / Biochimica et Biophysica Acta 1758 (2006) 563–564Hegedus' finding also provides a clue why second-site
mutations in the RXRmotif in the dodecapetide of NBF1 such as
R553Q, R553M and R555K partially corrected the F508del
CFTR mutant phenotype in model systems [16] and in CF
patients [17]. Some 20 years ago the commentator made the
clinical diagnosis of CF in a 7-year old patient in whom CF had
been suspected before but had been excluded because of normal
chloride concentrations in sweat tests. CFTR mutation analysis
uncovered themutationR553Q on one F508del CF chromosome
of this patient. In light of the newly gained knowledge, it can be
suspected that the inactivation of one RXR ER retention motif
partially rescued F508del CFTR from the ER quality control and
retained substantial residual function of CFTR in the patient's
sweat glands. This case illustrates how basic CFTR researchmay
unintentionally resolve puzzling CF disease phenotypes.
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